Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Annual Report and
Financial Statements for the year ended 31 December 2022
Crohn’s & Colitis UK – trading as Crohn’s & Colitis UK Registered Charity No. 1117148 (England and Wales) SCO38632 (Scotland) A company limited by guarantee in England and Wales No. 05973370
1
FA23-06
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Contents
Contents ............................................................................................................................................................................... 2 A Welcome from our Chair & Chief Executive ...........................................................................................................3 Who we are .......................................................................................................................................................................... 4 Strategic Report ................................................................................................................................................................. 5 Our Goal - We want everyone to understand Crohn’s and Colitis .................................................................. 5 Our Goal - We want to drive world class research into the disease .............................................................. 6 Our Goal - We want to support people and empower them............................................................................ 6 to be active participants in managing their life with Crohn’s and Colitis ..................................................... 6 Our Goal - We want earlier diagnosis and high quality, sustainable clinical care across the UK .......... 7 Enabling the charity to achieve our goals ............................................................................................................. 8 Plans for the future ...................................................................................................................................................... 8 Funding our work – our thanks to all our supporters ......................................................................................... 9 Governance, structure and management ................................................................................................................ 12 Legal status and objects ........................................................................................................................................... 12 Public benefit ................................................................................................................................................................ 12 Trustees and organisational structure ................................................................................................................. 12 Members ........................................................................................................................................................................ 13 Volunteers ..................................................................................................................................................................... 13 Employees ..................................................................................................................................................................... 13 Equality, Diversity and Inclusion (EDI) .................................................................................................................. 14 Subsidiary undertaking ............................................................................................................................................. 15 Risk review .................................................................................................................................................................... 15 Financial review ................................................................................................................................................................ 16 Compliance ................................................................................................................................................................... 16 2022 results.................................................................................................................................................................. 16 Reserves Policy ........................................................................................................................................................... 16 Cash and investments ............................................................................................................................................... 17 Pension costs ............................................................................................................................................................... 17 Staff remuneration ..................................................................................................................................................... 17 Grant making policies ................................................................................................................................................ 17 Research grants ..................................................................................................................................................... 17 Local grants ............................................................................................................................................................. 18 Statement of responsibilities of trustees .................................................................................................................. 19 Independent Auditor’s Report to the Trustees and Members of Crohn’s & Colitis UK ................................. 20 Financial statements ..................................................................................................................................................... 24 Consolidated Statement of Financial Activities ................................................................................................. 24 Balance Sheet ............................................................................................................................................................. 25 Consolidated Statement of Cash Flows ............................................................................................................... 26 Notes to the Accounts ............................................................................................................................................... 27 Administrative details .................................................................................................................................................... 42 Board of Trustees, officers and senior leadership team ................................................................................. 42 Professional services ................................................................................................................................................ 42 Follow us ....................................................................................................................................................................... 43
2
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
A Welcome from our Chair & Chief Executive
Being seen and heard
Nothing matters more to people living with Crohn’s and Colitis than being seen and heard. Living with an invisible condition can compound the daily challenges faced in education, work, home or social lives. Pain, fatigue and distressing bowel symptoms are not obvious on the outside but can profoundly affect everything you do. With the recognition and understanding of those around you, the burden can be eased and wellbeing dramatically improved.
That is why in 2022 as part of our new strategy, we have put more emphasis than ever before on Crohn’s and Colitis being seen and heard. And critical to that mission, is reflecting the enormous diversity of experience of our community both through developing better insight and intelligence for the charity and in the stories we tell to the world.
Our new public campaign focusing on early diagnosis, Cut the Crap, is intended not just to address the shocking figures of 1 in 4 taking more than a year to get diagnosed, but also to get recognition of Crohn’s and Colitis into the public mindset more generally. To date around 50,000 people have completed the symptom checker on our website and hundreds of thousands have seen the campaign through the press, radio, tv and on social media.
In putting the campaign together we have been mindful of the range of experiences of diagnosis and commissioned research to understand the evidence base in general, as well as taking deep dives into understanding the lived experience. You can see this diversity of experience and stories throughout our campaign.
We also recognise that we can have more impact by working with others. That is why we began a new collaboration in 2022 with other patient charities representing people living with lower gastrointestinal conditions and relevant healthcare professional organisations, to work together on a national lower gastrointestinal symptoms diagnosis pathway. We believe this powerful uniting of experience and expertise can drive real change in the consistency and quality of the diagnosis experience across many conditions.
And finally, it has been wonderful to see our community supporting each other and the charity in 2022 by taking part in more virtual social events, face to face Network events, community fundraising and campaigning. The support we can provide, the influence we have and the record-breaking money we raised in 2022 is down to your amazing participation – thank you!
Jackie Craissati Chair
Sarah Sleet Chief Executive
Signed 4 May 2023
3
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Who we are
We are the UK’s leading charity for Crohn’s and Colitis. Right now, over 500,000 people are living with these lifelong conditions that too many people have never heard of. We are working to improve diagnosis and treatment, and to fund research into a cure, to raise awareness and to give people the hope and confidence to live their lives.
OUR VISION:
Improved lives today A world free from Crohn’s and Colitis tomorrow
OUR MISSION:
We break taboos We drive pioneering research We support and bring people together We campaign to improve lives We are leading the fight against Crohn’s and Colitis
OUR VALUES:
We are ambitious We are compassionate We are stronger together
How are we working towards this vision?
We provide high quality information, practical help and support that enables people to manage their conditions. We believe people living with Crohn’s and Colitis should be able to live their lives to the full.
We work with the UK health sector to improve diagnosis, treatment and management of Inflammatory Bowel Disease (IBD) – Crohn’s Disease and Ulcerative Colitis are the two main types of IBD. We want everyone with the conditions to have access to the best healthcare possible.
We support life-changing research to increase knowledge of the causes, and the best treatments for Crohn’s and Colitis. We want to improve lives now and lead the mission to find a cure.
We campaign vigorously – for more knowledge, better services and more support for our ongoing fight against IBD.
And we’re doing it in line with our values of being compassionate, ambitious, and stronger together.
4
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Strategic Report
In 2022 we turned our focus to driving up public awareness, especially the urgent need to speed up diagnosis for thousands of people every year who are taking more than 12 months to get the diagnosis they need. We know that the longer it takes to get diagnosed, the more A&E visits, emergency surgery and serious medication will be the inevitable result.
As part of our new strategy, launched in 2022, we are determined to improve understanding of our diverse community. You could be any age, rich or poor, of any faith or none, of any ethnicity, sexuality, or gender. You could be anyone walking down any UK street. Whoever you are, a diagnosis of Crohn's or Colitis will be life changing. We commissioned and concluded research in the year to provide the facts and insight and used our communications and marketing to tell your story to the public and policymakers.
And with the generous support of our supporters, we beat our 2021 record income. As a result, we were able to fund more research, support more nurses, make it easier to find first class health information on our new website and attract more members than ever before.
Our Goal - We want everyone to understand Crohn’s and Colitis
We know that the understanding of friends, family, colleagues and service providers is fundamental to the well-being of our community and that is why we focused on driving public awareness in 2022.
-
Raising the profile of Crohn’s and Colitis continues to be a priority for the organisation. We collect stories from across our diverse community and feature these in blogs, on our social channels, in Connect magazine and importantly, share them with the media. The charity was quoted in news stories across the UK from regional press to national broadsheets, radio to TV. Over the full year there were 1,271 mentions of Crohn’s & Colitis UK in the media, which had the potential to be seen over 16 billion times.
-
We had regular conversations with government and the NHS across the UK to highlight the impact of delayed diagnosis, long waiting lists and difficulties accessing services for people with Crohn’s and Colitis. This resulted in plenty of media coverage, including in the Daily Mirror, the Daily Mail and multiple regional outlets.
-
We continued to campaign to keep public toilets open including writing to councils asking them to reconsider plans to close local toilets. We made progress with our Not Every Disability is Visible (NEDIV) campaign. In 2022 a further 16 organisations, including 13 police forces, installed our accessible toilet signage. Twenty-four employers joined our Are You IN? programme to support people with Crohn’s and Colitis, and other invisible conditions in the workplace and a further 90 companies contacted us for further information.
-
Well-known faces help to make an impact with the public, and we were delighted to receive support from a number of our Ambassadors in 2022. Sacha Dhawan, Tom Speight, Chris Tarrant and Lousie Thompson all kindly lent their support to our earlier diagnosis campaign, Cut the Crap. They attended our Westminster launch and used their voices online to raise awareness of our symptom checker. Siobhan-Marie O’Connor took part in the London
5
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Marathon, donned our charity vest, raising awareness and almost £2,500 for our work. We’d also like to thank Rylan Clark, Amy Dowden, Georgina Elliott and Ali Jawad for their continued support and for sharing their personal stories to raise the profile of the conditions and the work of the charity.
Our Goal - We want to drive world class research into the disease
Supporting research remains an important focus for the charity and in 2022 we were able to fund new and exciting research addressing the key priorities of people affected by Crohn’s and Coli t is and encourage even more to get involved in research.
-
We funded seven exciting new research projects in 2022 covering personalised medicine, fatigue, surgery and disease monitoring totalling funding of £545,000, up from the four projects worth £318,740 in 2021.
-
Six of the charity’s projects were able to complete in 2022 which have resulted, so far, in 12 publications including two reviews and two conference abstracts:
-
Non-invasive approaches to identify the cause of fatigue in IBD – Principal Investigator Professor Gordon Moran, University of Nottingham
-
Reducing Risk, Improving Outcomes: Development of Personalised Strategies to Reduce the Impact of Immunogenicity to Anti-TNF Therapy – Principal Investigator Dr Tariq Ahmad, University of Exeter
-
Blocking gut ‘self danger signals’ as treatment for IBD – Principal Investigator Dr Gwo-tzer Ho, University of Edinburgh
-
ImpaCt of bioLogic therApy on saRs-cov-2 Infection and ImmunITY (CLARITY IBD) – Principal Investigator Dr Tariq Ahmad, University of Exeter
-
Improving treatment adherence in young people with IBD – Principal Investigator Dr Gemma Heath, Aston University
-
The development and pilot testing of a patient decision aid to better support patients with Ulcerative Colitis choose between ongoing medical treatment and surgical treatment options – Professor Alan Lobo, Sheffield Teaching Hospitals NHS Foundation Trust
-
We launched a second grant round worth £240,000 focussed on early benefit for Crohn’s Disease, which was generously funded by The Leona M. and Harry B. Helmsley Charitable Trust. We will be making the awards in 2023.
-
We advertised 48 opportunities in 2022 to take part in or shape research into Crohn's and Colitis and helped over 1,800 people get involved.
-
We successfully livestreamed our patient research participation day for the third time, attracting 141 attendees on the day. It was viewed more than 250 times afterwards. The eight focus groups following the livestream allowed 59 people to work with researchers to shape projects, providing valuable insight.
Our Goal - We want to support people and empower them to be active participants in managing their life with Crohn’s and Colitis
We continue to be a trusted source of accurate and expert information as we move beyond the pandemic for thousands of people with Crohn’s and Colitis.
6
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
-
We were there for those needing support and information, answering nearly 10,000 queries via phone calls, emails and LiveChat providing information and support. Demand in 2022 was lower than 2021 (nearly 14,000 queries) which may be due to a reduction in the number of Covid related queries.
-
Our symptom information (94,000 page views) and treatment pages (77,000 views) are the most highly used website pages after our home page (440,000 views). We received over 1.9m total views of the information and support pages on the website.
-
Our new virtual social events continued to be a huge success, 70 events were held in 2022 enabling over 700 people to connect and support each other (56 events in 2021 with 565 attendees). This included new focused events – six in all - for parents and carers with a child with Crohn’s or Colitis.
-
Increasing confidence post the pandemic led to more face-to-face events being held by our Local Networks again to enable people to meet and support each other in their local area. Nearly 100 in person local events were held in 2022 compared to six in 2021.
-
Even more people tuned into our digital channels in 2022, extending the community further. We saw rises in followers on Facebook (2,000 additional followers) and Instagram (from 63,300 followers in 2021 to 71,000 in 2022, a rise of 12%). Across our four Twitter accounts (Primary account, Fundraising, Volunteering and Research) our number of followers increased to 58,879, up from 50,300 in 2021. Facebook Forum membership increased to over 59,000 supporters (up from 55,000 in 2021).
-
We held two Facebook Live events in 2022, one covering new treatments on the horizon and the other focused on diet. The combined reach was over 30,000 people.
Our Goal - We want earlier diagnosis and high quality, sustainable clinical care across the UK
Even before the pandemic, one in four people took more than a year to be diagnosed and nearly half visited A&E at least once before being diagnosed.
-
In November 2022 we launched our new public awareness campaign Cut the Crap which resulted in over 400 pieces of media coverage including the BBC, ITV, Channel 4, the Daily Mail and others. One of our case studies became the top read health story in the Sun.
-
We held parliamentary events in Westminster, Wales and Scotland where politicians and healthcare professionals heard directly from people living with Crohn’s and Colitis. Health ministers in Scotland and Wales publicly expressed support for the campaign.
-
We launched a new online symptom checker to help people experiencing symptoms such as stomach pain, diarrhoea and blood in poo find out if they needed to contact their GP. Over 30,000 people used our symptom checker and over 4,000 people backed our call for early diagnosis by the end of December.
-
We developed new training and education packages for general practitioners (GPs) working with the Royal College of GPs and others, to help GPs identify and support people with Crohn’s and Colitis. Our new partnership with NB Medical, delivering a webinar, podcast and education module, reached over 5,000 GPs in 2022.
7
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
-
In Scotland we secured the support of the Government to promote public awareness and the need for a diagnostic pathway. In Wales, we worked with the IBD Clinical Lead for Wales and the NHS Wales Health Collaborative work programme for IBD on topics such as access to tests and endoscopies. In Northern Ireland we worked with clinicians to call for implementation of diagnostic pathways.
-
As part of our Health Foundation funded programme AWARE-IBD, delivered in partnership with organisations in Sheffield, a Patient Reported Experience Measure was published and abstracts accepted for major international conferences, including annual meeting of the European Crohn’s and Colitis Organisation.
Enabling the charity to achieve our goals
2022 again brought focus on issues around inequality, particularly racial inequality. We recognised that as a charity we should be doing more to reflect the true diversity of those in the Crohn’s and Colitis community, and so our plans going forward embed priorities which will do just that. We undertook a review of our progress at the end of the year and developed a new policy and action plan, which includes a more proactive approach to addressing racism, agreed by the Board early in 2023.
We launched our new Learning and Development strategy for staff. To realise our ambition to be a learning organisation, we will invest in developing our people through a purposeful, consistent and blended approach to learning. Our staff now have access to over 16,000 courses on LinkedIn Learning and we have created a Manager Development Programme aligned to our competencies. We will continue to offer opportunities for development for the whole charity, including a focus on equality, diversity and inclusion.
The way that we work has changed and we have been able to attract talented staff from across the UK. This has allowed us to save costs and reduce our physical office space to support our people working in a hybrid manner. We continue to bring our people together throughout the year to develop our culture and learn from each other.
We are aware that the threat from cyber-attacks on the charity continue to increase. We take the security of our systems very seriously and in 2022 we demonstrated our commitment to cyber security by becoming Cyber Essentials certified. This is a government backed certification that we were awarded after a full audit of our security systems and processes.
Our new website launched in Spring 2022. In this first phase of website development, we improved the way the website looks, the navigation and developed new donation pages. We have introduced a My Page function so that users can produce their own, tailored ‘homepage’, where they can access articles and pages they have saved. If we compare launch date until December 2022 to the same period in 2021, the number of users has doubled, as have the number of sessions (when users are on the website for a period of time looking at various pages). Page views have increased from 1.3m up to 3.1m. Our new home page, developed in line with our new symptom checker which launched in November, received over 56,000 views from individuals in just two months.
Plans for the future
We will continue our strategy of increasing our evidence and insight around our diverse community and advocating to improve standards of diagnosis and care for all:
8
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Aim 1 Everybody Understands Crohn’s and Colitis
-
Invest in further proactive work with the media to boost recognition of the conditions and their impact. We will be strongly promoting the diversity of our community in these stories.
-
Identify further evidence needed to support understanding and the change needed on issues facing people with Crohn’s and Colitis.
-
Begin our programme of work to understand our community’s quality of life priorities and a dashboard to measure change in their experience in the priority areas.
Aim 2 Drive world class research
-
Launch a second research collaborative in a patient priority area.
-
Deliver a new targeted research call worth £500,000 and award £240,000 focused on interventions that will have an impact for people living with Crohn’s disease quickly.
Aim 3 Support and Empower people with Crohn’s and Colitis
-
Review and increase the accessibility of our much-valued information.
-
Support Local Networks to rebuild their activities as face-to-face events become possible once more alongside increasing the number of virtual social events.
Aim 4 Early and accurate diagnosis followed by high quality clinical care
-
Build our campaign on earlier diagnosis throughout 2023 targeting 18-34 year olds with more public awareness promotion.
-
Work with other patient charities and healthcare professionals’ bodies to develop a national diagnosis pathway for people with lower gastrointestinal symptoms.
-
Leading IBD UK to survey patients and gastroenterology services on the reality of IBD standards of care in 2023.
-
Recruit 10 nurses onto our badged nurse programme and continue to support nurses with training and development.
Funding our work – our thanks to all our supporters
2022 was another record-breaking year for income generation, just ahead of the 2021 income, with £7.2m raised. This is an incredible achievement, and it is thanks to everyone who went above and beyond in support of the charity. Thank you!
Over 75,000 people fundraised for, or donated to, us in 2022 - more than double the number in 2021. Thank you to everyone who took on a challenge, made a donation or participated in an activity for us. The funds and awareness you raise are vital.
Our fundraisers excelled themselves, from raising over £1.7m from birthday collections to conquering Mount Everest and everything in between. We also had more nominations for our Alex Demain Awards than ever before. The awards, which celebrate our young fundraisers, are named in memory of Alex Demain, a muchloved colleague who died in 2015. This year’s six winners had taken on challenges such as abseiling, a coffee morning and concert, and My Walk It. These incredible young people have inspired us all.
We were delighted to see our new virtual events take off, with our 60-mile Challenge raising £154,000, and our Big Winter Workout proving a winner with over 4,000 people registering in December to exercise for 31 mins every day in January 2023! The success of the 2022 summer’s My Walk It, our virtual walking event, raised almost £140,000 with over 2,400 supporters. We were also delighted to have the support of comedian, Joe Lycett, who allowed us to raise funds at his comedy gigs across the UK. Fifty volunteers collected donations in Bath, Brighton, Leeds, London, Manchester, Nottingham, Oxford and Southend, raising over £10,000. The much-loved Prestonfield Spring Ball, held in Edinburgh raised over £17,500.
9
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Our Lottery fundraiser saw success, raising over £144,000 for the charity, but even more excitingly producing our first big lottery winner. Crohn’s & Colitis UK member Janis Dobson won the top prize of £25,000. Janis was thrilled, especially as the day she was informed she’d won was, coincidentally, also her birthday!
We secured just over 100 grants from Charitable Trusts and Foundations achieving £1.1m. This included funding from the Health Foundation towards AWARE-IBD, a project which aims to empower people with Crohn's and Colitis to improve their care based on what matters to them, resulting in better outcomes and experiences of care. We were once again supported by The Leona M. and Harry B. Helmsley Charitable Trust, which awarded two grants totalling just short of £0.5m. The first grant was towards the operational costs of running our multi-channel Helpline services. The second enabled us to uniquely develop and deliver a new targeted call for research into Crohn’s Disease with the aim of achieving early patient benefits. Other major grants included £25,000 from the Robert Luff Foundation towards our research programme and £20,000 from the Gerald Leigh Charitable Trust towards our Helpline services.
Our corporate partners donated over £600,000 to us in 2022. We received grants towards our Early Diagnosis Campaign from pharmaceutical partners Bristol Myers Squibb and AbbVie. We also received grants from Janssen towards our study into the economic cost of IBD and Norgine towards our information service. Corporate partners PB Mortgages raised funds for us by scaling Ben Nevis, with plans to conquer all the Yorkshire Peaks in 2023, and we were delighted to receive support from YUYU bottle and Notch again this year. We were also delighted to see so many of our corporate partners actively supporting our Earlier Diagnosis campaign by sharing the petition and symptom checker with staff and customers.
2022 saw the launch of our new service, Crohn’s & Colitis UK Healthcare Direct. Supporters who have a stoma can sign up to receive stoma products and medication delivered direct to their door. We piloted the service with members in 2022. As feedback has been extremely positive, we will be extending the service to all supporters in 2023. Crohn’s & Colitis UK Healthcare Direct is delivered in partnership with Bullen Healthcare, the UK’s largest Independent Dispensing Appliance Contractor (DAC) and a family-owned business.
We secured and retained partnerships, or received support from the following companies to whom we extend our sincere thanks:
AbbVie Arena Pharmaceuticals Bristol Myers Squibb Galapagos UK Janssen Next PLC Norgine PB Mortgages Peak Scientific Sheet Plant Association Takeda UK Ltd Tezlom - Dartford YuYu Designs Ltd
10
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Trusts and Foundations
We would like to express our sincere and heartfelt gratitude to all our Trust and Foundation and statutory funders, including:
C A Redfern Charitable Foundation Cecil And Hilda Lewis Charitable Trust February Foundation Gerald Leigh Charitable Trust John James Bristol Foundation Lawson Trust Lord Leverhulme's Charitable Trust Margaret Giffen Charitable Trust National Lottery Community Fund England Pilkington Charities Fund Reo Stakis Charitable Foundation Robert Luff Foundation Schuh Trust Simon Gibson Charitable Trust The Bothwell Charitable Trust The Charles and Elsie Sykes Trust The Edward Cadbury Charitable Trust The Health Foundation The Leona M. and Harry B. Helmsley Charitable Trust The Light Fund The Waterloo Foundation Wixamtree Trust
We greatly value and rely upon the trust of our supporters, and would like to take this opportunity to recognise our major supporters:
Mrs Jane and Mr Tim Butler Mr Andrew Edwards
We are also grateful to a number of other major supporters who wish to remain anonymous.
Our fundraising is conducted in compliance with the law and recognised good practice. We support the Fundraising Regulator’s Promise, and we are a member of the Fundraising Regulator’s scheme, which hold members to set standards for charitable fundraising, and we proudly display its logo on all our public fundraising materials. To maintain our supporters’ trust we are open, honest, fair, and legal in our fundraising practice. There were no compliance issues with the Fundraising Standards we have adopted. In 2022 we received nine complaints (seven in 2021) about our fundraising, representing a tiny proportion of our interactions.
We employ two professional fundraising organisations to recruit payroll giving regular donors and partner with third party platforms to enable online fundraising such as JustGiving. Our lottery and raffles are licenced and regulated by the Gambling Commission, and we ensure that appropriate information and support is in place to tackle problem gambling. Fundraising activities which include children and/or adults at risk must comply with our Safeguarding Policy, and staff are trained in safeguarding principles. Crohn’s & Colitis UK staff are guided by our Fundraising Policy and have a responsibility to thoroughly understand and comply with the policy, within which we provide guidance on the legal aspects of fundraising and our ethical commitments
11
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Governance, structure and management
Legal status and objects
Crohn’s & Colitis UK is a charity registered in England and Wales no. 1117148 and in Scotland no. SCO38632 and is a company limited by guarantee in England and Wales no. 05973370.
The charity is governed by its Articles of Association, last amended in September 2017.
The charity’s objects, as set out in its constitution, are:
-
the relief of those suffering from Ulcerative Colitis, Crohn’s Disease or related inflammatory bowel diseases (together, generally referred to as IBD) including the support of those who care for them.
-
the promotion of the welfare of those suffering from Ulcerative Colitis, Crohn’s Disease or related inflammatory bowel diseases.
-
the advancement of education and research into the causes, prevention, treatment and cure of Ulcerative Colitis, Crohn’s Disease or related inflammatory bowel diseases, improvements in the management of the conditions, and the publication of the results of such research.
Public benefit
In accordance with the Charities Act 2011, Crohn’s & Colitis UK is required to confirm that the activities it undertakes to achieve its objectives are all carried out for public benefit as described by the Charity Commission. It should be noted that all the charity’s information and support services are open to nonmembers to use as well as members. We have demonstrated in this report how we have met the objects above.
Trustees and organisational structure
In May 2022 we said goodbye to our chair of 6 years, Sue Cherrie, who led the charity through some of its toughest times during the COVID-19 pandemic. And we welcomed our new chair, Dr Jackie Craissati MBE, recruited through a transparent and competitive process. Jackie is a long-time member of the charity. Her professional background is in clinical and forensic psychology, having worked in public sector roles in the NHS and criminal justice system. She is currently the Chair of Kent and Medway NHS trust and has recently been appointed as Chair of Dartford & Gravesham NHS Trust.
The constitution provides for a Board of Trustees comprising at least seven and not more than twelve Trustees who may be appointed by a decision of the Trustees or elected at the annual general meetings of members. New Trustees are appointed through a transparent recruitment and selection process and are elected for an initial period of three years following which they are eligible for re-election for two further terms of three years. They are inducted on appointment and receive appropriate training and development throughout their tenure including safeguarding and in relation to equality, diversity and inclusion.
During the year we welcomed two new Trustees, Manpreet Dhesi and Ian Patrick. They will bring their valuable professional expertise in strategic communications, government relations and strategic advice to the private sector on geo-political risk. And we said goodbye to two Trustees, Sarah Denselow and Alice Rath. Sarah served nine years as a Trustee guiding the charity in that time through many improvements in governance as National Secretary. Alice served two years, bringing a fresh perspective as one of our youngest Trustees. We are grateful to both for their time and commitment.
12
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
The Board of Trustees has responsibility for the governance and strategic direction of the charity, ensuring that the charity upholds its ethos and values and delivers its objectives. Authority for the operation of the charity is delegated to the Senior Leadership Team (SLT), led by the Chief Executive, who reports to the Trustees to the levels described in a Scheme of Delegation.
The Trustees have the power to co-opt advisers as non-voting members of the Board and appoint committees. There were three committees of the Board in 2022: Finance and Audit, People and Organisational Development, and Research Strategy and Funding.
Towards the end of 2022, the charity began the establishment of a Young Adults Advisory Panel to provide young adults’ (18 – 28 years) perspective on the charity’s strategy and programmes of work to the Board. Amelia Ehren was appointed chair and recruitment of the remaining panel was carried out in 2023.
The Trustees review progress against the charity’s aims and objectives at every Board meeting and receive interim updates on important matters through Board Committees and electronic communication.
The Trustee Board held five formal meetings in 2022.
Members
In a testament to the strength of our community, membership numbers broke 50,000 for the first time (up from 47,000). As well as raising much-needed funds, members continued to access support and information through Connect magazine and bespoke member communications.
Our AGM was held online on 17 September with 76 members present throughout. Members voted to approve our 2021 Annual Report and Financial Statements, and they voted in favour of the re-appointment of the charity’s auditors, Price Bailey. We are especially thankful to speaker Professor Miles Parkes, who shared a presentation about predicting disease course in IBD – why it matters and how we might do it.
Volunteers
Volunteers continue to play a vital role in the work of the charity, and we value the time, dedication and support we receive from all our volunteers and supporters. We are fortunate to have 934 volunteers registered with the charity – up from 870 in 2021.
Employees
The charity started the year with a complement of 63 staff and finished with 75 (71 full time equivalent average in year) to deliver the charity’s growing agenda.
It is the charity’s policy to provide equal opportunities to job applicants and employees of any race, nationality, ethnic origin, marital status, religion or belief, gender, disability, sexual orientation, age or employment status. The charity does not condone or tolerate any form of discrimination in its recruitment or employment practices.
13
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Equality, Diversity and Inclusion (EDI)
The charity has a strong commitment to EDI at all levels placing a high value on a truly embedded and inclusive culture, and as our diverse workforce grows, we want everyone to know that they work in a safe, supportive and inclusive environment where they can be themselves and deliver their best.
The information below is the position at the end of March 2022, and we have not included “unidentified or prefer not to say” data.
----- Start of picture text -----
Proportion of staff gender by pay quartile
Upper quartile 18% 82%
Upper middle
12% 88%
quartile
Lower middle
6% 94%
quartile
Lower quartile 12% 88%
Male Female
----- End of picture text -----
14
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Subsidiary undertaking
NACC Merchandise Ltd is a wholly owned subsidiary company of the charity. The principal activity of the company is the sale of Christmas cards and merchandise. Taxable profits of £6,347 (2021: £2,390) were transferred to the charity as Gift Aid under a deed of covenant arrangement. More information on the results of NACC Merchandise Ltd is given in note 10 of the Financial Statements.
Risk review
The Trustees, with input from the Chief Executive and staff, have conducted a review of the risks to which the charity is exposed in its ongoing activities. In particular, the Trustees considered:
-
the type of risks the charity faces
-
the level of risks they regard as acceptable
-
the likelihood of the risk concerned materialising
-
the charity’s ability to reduce the incidence and impact of risks that have been identified
-
the costs of operating specific controls relative to the benefit obtained.
The Trustees review risks in relation to any new developments proposed and the Finance and Audit Committee reviews the full risk register (maintained by the Senior Leadership Team ) at every business meeting. The top line risks are also discussed at the full Trustees’ meeting on a quarterly basis.
The Trustees identified the following principal risks facing the charity in 2022:
-
the continuing uncertainty in income planning as we exited the pandemic which we mitigated through a business plan that could flex up and down in terms of expenditure with regular review throughout the year.
-
challenging recruitment and retention conditions in the external market could lead to a lack of staff resource threatening programme delivery which was mitigated by implementing a new pay and reward framework, flexible working patterns and investment in learning and development to make the charity an attractive employer.
-
ensuring that charity activities link to strategic plan KPIs mitigated by creating clear strategic aim rationales for activity planning.
-
independence for Scotland continued to feature early in the year and the charity demonstrated its value to the four nations. We continue to invest in advocacy and policy work specifically in the four nations and share that work with our Scottish supporters to demonstrate our ongoing relevance.
15
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Financial review
Compliance
The financial results for the year are set out in the Consolidated Statement of Financial Activities (SOFA). This represents the total income and expenditure relating to all activities in the year, made up of the work of the charity at national level, in Local Networks and the activities of the trading company, NACC Merchandise Ltd.
The figures in the following paragraphs are taken from the SOFA and from the notes to the Financial Statements.
2022 results
During 2022 the charity has made an overall surplus of £440,126 (2021: £2,605,055) split between an unrestricted funds surplus of £657,951 (2021: £1,935,457) and restricted funds deficit of £217,825 (2021 surplus: £669,598). This healthy surplus was much larger than anticipated as income was significantly higher than budgeted although only fractionally ahead of the previous year. Legacies again performed particularly well but are notoriously difficult to budget accurately for.
In terms of expenditure, this increased materially compared to 2021 at £6,484,377 (2021 £4,768,412) with planned gradually increasing expenditure in all areas (except Campaigns) with the biggest increase being on research at £759,951 (2021 £447,088).
Reserves Policy
The Reserves Policy outlines a framework to balance the need to maintain adequate funds to sustain future activity
Total reserves increased to £5,733,759 (2021: £5,293,633) after the unbudgeted surplus for the year.
The charity holds restricted funds to the value of £803,867 (2021: £1,021,692), which may only be used in accordance with specific restrictions imposed by the donor.
The charity also holds unrestricted funds to the value of £4,929,892 (2021: £4,271,941) of which £716,893 (2021: £810,887) were designated funds as follows:
-
Tangible Fixed Assets - A designated fund has been created that represents the net book value of tangible fixed assets insofar as these funds are not available for immediate use.
-
Intangible Fixed Assets - A designated fund has been created that represents the net book value of intangible fixed assets insofar as these funds are not available for immediate use.
-
Local Networks retained funds - The Trustees also agreed that any accumulated surpluses from the Volunteer Networks should be held for future use by Networks, and a designated fund has been established for this purpose. Networks are required to utilise these funds within two years of the end of the year in which they are reported.
The balance of unrestricted funds not otherwise designated represents the free reserves of the charity. The Trustees have agreed that in order to maintain adequate levels of working capital to fund day-to-day operations, and to protect the charity from income fluctuations and seasonal volatility, free reserves should be a minimum of £1.3m. This is to represent a combination of an unexpected and immediate reduction in
16
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
unrestricted income, alongside the need to meet core budgeted unrestricted expenditure allowing the charity to continue to operate and maintain its core services for six months.
As the actual level of unrestricted reserves, at £4.2m at the year end, exceeds this minimum cover, we are planning a hugely increased programme spend for 2023 to utilise this excess to maximum effect in line with our strategy.
Cash and investments
The liquid funds of the charity are represented by cash deposits including £213,971 (2021: £232,873) held by our Local Networks, and investments held in a charity restricted ethical investment fund managed by CCLA Investment Management. At the year-end there were £1,910,453 (2021: £1,809,670) held in interest bearing accounts.
Pension costs
The charity operates a defined contribution pension scheme, established in 2015 through Legal & General. New employees are automatically enrolled in the scheme, and staff that may subsequently opt to leave the scheme will be re-enrolled after three years.
Staff remuneration
Crohn’s & Colitis UK is committed to ensuring a proper balance between (i) paying our staff fairly so that we attract and retain the very best people with the right experience and leadership qualities and (ii) careful management of our charity funds. In so doing we ensure the greatest effectiveness in delivering our charitable objectives and meeting the needs of our beneficiaries.
Staff salaries are determined by reference to bands that take account of the levels of capability and experience required, authority and discretion levels. Our salaries need to be competitive within the charity sector, but we do not aim to compete on pay with the public or private sectors. We undertook a full benchmark of salaries against the market in 2022.
Salaries of the Senior Leadership Team, including the CEO, are agreed by the Board of Trustees and will take account of the past year’s achievements, environmental and market conditions, and of sector comparison. Our work is dependent on voluntary donations and we act in an open and transparent way that respects the money, time and energy given by donors and volunteers. In our commitment to openness, we disclose information about senior staff salaries within our annual report. This is in line with recommendations and guidelines from the National Council for Voluntary Organisations (NCVO).
Grant making policies
Research grants
Applications are considered by members of the Awards Panel, comprising academic and medical specialists as well as lay representatives. External specialist referees are asked to comment confidentially on applications. Grants awarded in previous years are still progressing.
17
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
The Research Strategy and Funding Committee review and approve the recommendations of the panel by delegated authority from the Board of Trustees. Our website has an area dedicated to reporting back, in ‘plain English’, on the findings from the research projects we fund.
Crohn’s & Colitis UK has been awarded a Certificate of Good Practice for its peer review procedures by the Association of Medical Research Charities. Grants are normally made for periods of up to three years, with reports required at annual intervals. Funds are set aside for the total cost of the project in the year of the award.
Local grants
Local Networks may make grants to local hospitals to support staff professional development or enhance aspects of the provision for IBD patients. Three grants were awarded in 2022 totalling nearly £5,000, buying items such as infusion chairs and televisions for endoscopy suites in hospitals.
18
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Statement of responsibilities of trustees
The Trustees (who are also directors of Crohn’s & Colitis UK for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the directors are required to:
-
select suitable accounting policies and then apply them consistently
-
observe the methods and principles in the Charities SORP FRS102 (2019)
-
make judgements and estimates that are reasonable and prudent
-
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the Financial Statements
-
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
The Strategic Report and The Financial Review were approved by the Trustees on 4 May 2022 and signed on their behalf by:
Dr Jackie Craissati MBE – Chair of the Board of Trustees 4 May 2023
19
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Independent Auditor’s Report to the Trustees and Members of Crohn’s & Colitis UK
Opinion
We have audited the financial statements of Crohn’s & Colitis UK (the ‘parent charitable company’) and its subsidiaries (the 'group') for the year ended 31 December 2022 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheet, the Group Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
-
give a true and fair view of the state of the group’s and parent charitable company’s affairs as at 31 December 2022, and of the group’s incoming resources and application of resources including its income and expenditure for the year then ended;
-
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-
have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group and parent charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.
20
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Other information
The other information comprises the information included in the trustees’ annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006.
In our opinion, based on the work undertaken in the course of the audit:
-
the information given in the trustees' report (which includes the strategic report and directors’ report prepared for the purposes of company law) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
-
the strategic report and the directors’ report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors’ report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities and Trustees Investment (Scotland) Act 2005 and Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:
-
adequate and proper accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
-
the parent charitable company’s financial statements are not in agreement with the accounting records and returns; or
-
certain disclosures of directors’ remuneration specified by law are not made; or
-
we have not received all the information and explanations we require for our audit.
Responsibilities of trustees
As explained more fully in the trustees’ responsibilities statement, the trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
21
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.
Auditor responsibilities for the audit of the financial statements
We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists.
Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
We gained an understanding of the legal and regulatory framework applicable to the Charitable Group and the sector in which it operates and considered the risk of the Charitable Group not complying with the applicable laws and regulations including fraud in particular those that could have a material impact on the financial statements. This included those regulations directly related to the financial statements, including financial reporting and tax legislation. In relation to the operations of the Charitable Group and parent this included compliance with the Companies Act 2006, Charities Act 2011, Charities Commission, OSCR and SORP 2019.
The risks were discussed with the audit team and we remained alert to any indications of non-compliance through the audit. We carried out specific procedures to address the risks identified. These included the following:
Reviewing minutes of Board meetings, reviewing any correspondence with the Charity Commission, agreeing the financial statement disclosures to underlying supporting documentation, and enquiries of management and officers of the Charitable Group. We have also reviewed the procedures in place for the reporting of any incidents to the Trustee Board including serious incident reporting of these matters as necessary with the Charity Commission.
Management override: To address the risk of management override of controls, we carried out testing of journal entries and other adjustments for appropriateness. We reviewed systems and procedures to identify potential areas of management override risk.
We also assessed management bias in relation to the accounting policies adopted and in determining significant accounting estimates, including treatment of legacies and grant income, valuation of investments and the amortisation rates of intangible assets.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with
22
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities is available on the FRC's website
at: https://www.frc.org.uk/auditors/audit-assurance/auditor-s-responsibilities-for-the-audit-of-thefi/description-of-the-auditor%E2%80%99s-responsibilities-for. This description forms part of our auditor’s report.
Use of our report
This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company’s members as a body and the charitable company’s trustees as a body, for our audit work, for this report, or for the o p inions we have formed.
Michael Cooper-Davis FCCA ACA (Senior Statutory Auditor) Dated 05 May 2023
For and on behalf of: Price Bailey LLP Chartered Accountants Statutory Auditors 8th Floor, Dashwood House 69 Old Broad Street London EC2M 1QS
23
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Financial statements
Crohn’s & Colitis UK
Consolidated Statement of Financial Activities
Including income and expenditure For the year ended 31 December 2022
| Note Income : Donations and legacies 2 Charitable activities 5 Other trading activities 3 Investments 4 Other Total income Expenditure : Raising funds 9 Charitable activities: Research 11 Helplines Knowledge and Information Communications Early Diagnosis Evidence and Insight Quality Improvements Campaigns Networks & volunteering Membership Total expenditure 6 Net income before investment gains/(losses) Gains/(losses) on investments 17 Net income Transfers between funds 15 Net movement in funds Reconciliation of funds: Total funds brought forward Total funds carried forward |
Unrestricted funds (inc. designated) funds note 22) £ 3,122,623 755,794 1,549,388 95,884 8,889 5,532,578 1,905,600 24,991 165,889 60,237 441,336 238,943 242,691 346,004 371,163 94,742 674,754 4,566,350 966,228 (312,141) 654,087 3,864 657,951 4,271,941 4,929,892 Note 22 |
Restricted funds £ 320,031 8,301 1,375,734 - - 1,704,066 - 734,960 367,271 323,430 62,000 - - 374,312 56,054 - - 1,918,027 (213,961) - (213,961) (3,864) (217,825) 1,021,692 803,867 Note 23 |
Total Total funds funds 2022 2021 £ £ 3,442,654 3,776,470 764,095 716,935 2,925,122 2,654,315 95,884 46,238 8,889 16,170 7,236,644 7,210,128 1,905,600 1,661,931 759,951 447,088 533,160 529,951 383,667 233,788 503,336 282,206 238,943 - 242,691 - 720,316 402,942 427,217 511,742 94,742 82,674 674,754 616,090 6,484,377 4,768,412 752,267 2,441,716 (312,141) 163,339 440,126 2,605,055 - - 440,126 2,605,055 5,293,633 2,688,578 5,733,759 5,293,633 |
|---|---|---|---|
The Statement of Financial Activities includes all gains and losses in the year. All of the above amounts relate to continuing activities.
The net surplus of the Charitable Company for the year was £440,126 (2021 £2,605,055).
24
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Financial statements Crohn’s & Colitis UK Balance Sheet
For the year ended 31 December 2022
| Note Fixed assets Intangible assets 16 Tangible assets 16 Investment 17 Total Fixed Assets Current assets Debtors 18 Cash at bank and in hand 19 Total Current Assets Liabilities Creditors: amounts falling due within one year 20 Net current assets Total assets less current liabilities Creditors: amounts falling due after one year 20 Provisions for liabilities 21 Total net assets The funds of the charity Unrestricted funds 22 Designated funds held nationally Designated funds held by Networks General Reserve Fund held nationally Total unrestricted funds Restricted funds 23 Held nationally Total restricted funds Total charity funds |
2022 2021 £ £ 168,605 313,247 314,736 294,923 2,443,582 2,255,722 2,926,923 2,863,892 2,754,266 2,062,050 2,610,762 2,242,771 5,365,028 4,304,821 (1,990,650) (1,435,803) 3,374,378 2,869,018 6,301,301 5,732,910 (459,542) (439,277) (108,000) - 5,733,759 5,293,633 483,341 608,170 233,551 202,717 4,213,000 3,461,054 4,929,892 4,271,941 803,867 1,021,692 803,867 1,021,692 5,733,759 5,293,633 Group* |
2022 2021 £ £ 168,605 313,247 314,735 294,923 2,443,583 2,255,723 2,926,923 2,863,893 2,769,806 2,062,050 2,538,678 2,229,536 5,308,484 4,291,586 (1,934,107) (1,422,569) 3,374,377 2,869,017 6,301,300 5,732,910 (459,542) (439,277) (108,000) - 5,733,758 5,293,633 483,342 608,170 233,551 202,717 4,212,999 3,461,054 4,929,892 4,271,941 803,867 1,021,692 803,867 1,021,692 5,733,759 5,293,633 Charitable Company |
|---|---|---|
The accounts, which comprise the consolidated statement of financial activities, the balance sheets and the related notes, were authorised for issue by the Board of Trustees on 4 May 2023 by:
| Company Number : | 05973370 |
|---|---|
| English Charity Number : | 01117148 |
| Scottish Charity Number : | SC038632 |
Jackie Crassati, Chair
- Group represents the consolidation of the Charity with its trading company.
25
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK Consolidated Statement of Cash Flows For the year ended 31 December 2022
| Cash flows from operating activities Net cash provided by (used in) operating activities Cash flows from investing activities: Investment income Sale/(purchase) of investments Net cash provided by (used in) investing activities Change in cash and cash equivalents in the year Cash and cash equivalents at 1 January Cash and cash equivalents at 31 December Net income/(expenditure) for the year (as per the SOFA) Depreciation charges Unrealised (Gains)/losses on investments Investment income (Increase)/decrease in debtors Increase/(decrease) in creditors Net cash provided by (used in) operating activities Analysis of cash and cash equivalents Cash in hand Notice deposits Total cash and cash equivalents (a) Analysis of changes in net debt Cash and Cash equivalents B/D Cash flows Cash and Cash equivalents C/D Reconciliation of net income/(expenditure) to net cash flow from operating actvites |
2022 2021 £ £ 841,553 1,204,869 95,884 46,238 (500,000) (1,000,000) (404,116) (953,762) 437,437 251,107 2,173,325 1,922,218 2,610,762 2,173,325 440,126 2,605,055 209,537 235,300 296,879 (163,339) (95,884) (46,238) (671,408) (1,356,654) 662,303 (69,255) 841,553 1,204,869 700,309 433,101 1,910,453 1,809,670 2,610,762 2,242,771 2,173,325 1,922,218 437,437 251,107 2,610,762 2,173,325 Group* |
2022 2021 £ £ 841,553 1,204,869 95,884 46,238 (500,000) (1,000,000) (404,116) (953,762) 437,437 251,107 2,173,325 1,922,218 2,610,762 2,173,325 440,126 2,605,055 209,537 235,300 296,879 (163,339) (95,884) (46,238) (671,408) (1,356,654) 662,303 (69,255) 841,553 1,204,869 700,309 433,101 1,910,453 1,809,670 2,610,762 2,242,771 2,173,325 1,922,218 437,437 251,107 2,610,762 2,173,325 Group* |
2022 2021 £ £ 856,815 1,231,184 95,884 46,238 (500,000) (1,000,000) (404,116) (953,762) 378,588 277,422 2,085,980 1,808,558 2,464,568 2,085,980 440,126 2,605,055 209,537 235,300 370,990 (163,339) (95,884) (46,238) (707,757) (1,317,105) 639,803 (82,489) 856,815 1,231,184 628,226 419,866 1,910,453 1,809,670 2,538,679 2,229,536 2,085,980 1,808,558 378,588 277,422 2,464,568 2,085,980 Charitable Company |
|---|---|---|---|
| 1,204,869 | |||
| 46,238 (1,000,000) |
|||
| (953,762) | |||
| 251,107 1,922,218 |
|||
| 2,173,325 2,605,055 235,300 (163,339) (46,238) (1,356,654) (69,255) |
|||
| 1,204,869 | |||
| 433,101 1,809,670 |
|||
| 2,242,771 1,922,218 251,107 |
|||
| 2,173,325 |
- Group represents the consolidation of the Charity with its trading company.
26
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK Notes to the Accounts
For the year ended 31 December 2022
- 1 Accounting policies
The registered office of Crohn's and Colitis UK is 1 Bishops Square, Hatfield, AL10 9NE
Basis of accounting
The charity is a public benefit entity and the accounts have been prepared under the historical cost convention and in accordance with the Statement of Recommended Practice for Charities (SORP 2019), FRS102, the Companies Act 2006, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, relevant law and accounting standards and are reported in £ sterling.
Going Concern
The Trustees have reviewed the financial plans and cash flows for the coming twelve months and also a longer term plan for the next two years where the charity and group is looking to reduce its existing reserves and incur an annual deficit, and as such are satisfied that it is appropriate for the accounts to be prepared on a going concern basis, and as explained in the Trustees Report.
Group financial statements
These financial statements consolidate the results of the charity and its wholly owned trading subsidiary NACC Merchandise Limited. A separate statement of financial activities (SOFA) and separate statement of cash flows are not presented because the charity has taken advantage of the provisions of paragraph 408 of the Companies Act 2006.
Local Networks
The charity had forty seven local networks that were active to some degree during the year. All active networks are required to make returns of income and expenditure for the year which are included in the financial statements.
Income
-
i) All income is included in the accounts without netting off expenditure.
-
ii) Members' subscriptions are taken to income in full in the year of receipt.
-
iii) Investment income is taken to income on the accruals basis.
-
iv) Donations received are treated as unrestricted funds unless they are specifically designated by the donor.
-
v) Legacy entitlement is taken on a case by case basis as the earlier of the date when the charity is aware that probate has been granted, and either:
-
the estate has been finalised and estate accounts have been received by the charity: or
-
notification has been made by the executor(s) to the charity that a distribution will be made; or
-
when a distribution is received from the estate.
Receipt of a legacy is only considered probable when the amount can be measured reliably.
In estimating the value of legacies at the year end the trustees have exercised their judgement based on the available information and the appropriate application of the Charities SORP.
Expenditure
-
i) Expenditure is charged on an accruals basis.
-
ii) The full cost of booklets, leaflets etc. is charged in the year the expenditure is incurred.
-
iii) Research grants are charged to expenditure at the time the funding commitment is agreed with the third party.
The majority of grants, which can be for more than one year, are paid quarterly in arrears. For administrative reasons it can take some time for the grantee to appoint suitable staff and consequently some grants may remain partly unpaid at the year end.
Full provision is made for amounts allocated but not yet paid and this provision is shown as a creditor falling due within one year and after one year.
-
iv) The majority of costs are directly attributable to specific activities. Costs incurred in respect of the charitable activities include elements of staff costs and attributable support costs.
-
v) Support costs are those costs which are common to all areas of the organisation, including premises and office operating costs. Included in support costs are Governance costs, which comprise those costs associated with meeting the constitutional and statutory requirements of the charity. Support costs are allocated across all areas of activity on the basis of staff time spent on each activity.
27
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK Notes to the Accounts For the year ended 31 December 2022
- 1 Accounting policies (continued)
Expenditure continued
-
vi) Governance costs include both the direct costs of the charity meeting its statutory obligations and a portion of officer and overhead time spent on the strategic direction of the organisation and compliance with constitutional and statutory requirements.
-
vi) Irrecoverable VAT is charged to the SOFA.
Debtors
Debtors are stated in the balance sheet at estimated net realisable value, being the invoiced amount less provisions for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand and interest bearing deposits.
Creditors
Expenditure is recognised in the accounts on the accruals basis, giving rise to creditors at the year end. Other than grants (discussed below), these are all payable within one year.
Grants
Grants are split between current and non-current liabilities. The provision for a multi-year grant is recognised at its actual value where settlement is due over more than one year from the date of the award, there are no unfulfilled performance conditions that would permit the charity to avoid making the future payment(s) and settlement is probable.
The effect of discounting is considered immaterial in both current and prior year ends.
Capitalisation and depreciation of tangible and intangible fixed assets
All fixed assets are initially recorded at cost. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Leasehold improvements straight line over the lease period Fixtures and fittings 25% per annum straight line Software development 20% per annum straight line Computer equipment 33% per annum straight line
Capital commitments are disclosed as at the year end.
Fixed asset investments
Fixed asset investments are included at market value at the balance sheet date. Any gain or loss on revaluation is taken to the SOFA.
Pension Contributions
The charity makes contributions for employees to a group personal pension scheme. This is a defined contribution scheme to which the charity makes employer's contributions of either 5% or 8% of gross pay.
Funds Accounting
Funds held by the charity are:
Unrestricted general funds - these are funds which can be used in accordance with the charitable objects at the discretion of the Trustees.
Designated funds - these are funds set aside by the Trustees out of unrestricted general funds for specific future purposes in accordance with the development plans of the organisation and to enable the completion of existing projects.
Restricted funds - these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular purposes.
These funds are further divided between those held Nationally and those held by Local Networks. Further explanation of the nature and purpose of each fund is included in the notes to the accounts.
Operating leases
Rentals applicable to operating leases where substantially all the benefits and risks of ownership remain with the lessor are charged to the SOFA on a straight line basis as they arise.
28
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohns & Colitis UK Notes to the Accounts For the year ended 31 December 2022
- 1 Accounting policies (continued)
Financial Instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, which is at cost, with the exception of:
-
Investments are measured at their fair value as at the balance sheet date;
-
Fixed assets are measured at cost less depreciation and amortisation; and
-
All other assets and liabilities are held at cost.
The investments note 17 details the historic cost of the investments and the unrealised gains to arrive at their fair value.
Judgements and key sources of uncertainty
No judgements (apart from those involving estimates) have been made in the process of applying the above accounting policies.
The key assumptions concerning the future and key sources of estimation uncertainty at the key reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year include:
-
Estimation of the useful economic life of buildings, furniture and office equipment and IT equipment.
-
Estimation of the recoverable amount of legacy debtors.
29
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
| 2 Donations and legacies Donations from members Donations to Local Networks Other donations (in memoriam, payroll, gift aid) Legacies Research Unrestricted 3 Income from other trading activities National fundraising External turnover of trading subsidiary 4 Investment income and interest Other Interest: Charity investment income Charity bank interest 5 Income from charitable activities Subscriptions 6 Expenditure on charitable activities Direct Direct Support staff other costs costs costs £ £ £ Raising funds (note 9) 848,040 631,258 426,302 Charitable activities Grantmaking (note 11) 208,514 545,712 5,725 Helplines 407,410 87,753 37,997 Knowledge and Information 189,835 180,035 13,797 Evidence and insight 94,110 92,993 55,588 Early diagnosis - 238,943 - Communications 225,669 176,579 101,088 Quality Improvements 269,600 316,734 133,982 Campaigns 170,024 172,178 85,015 Networks & Volunteering 63,943 9,098 21,701 Membership costs 295,507 224,695 154,552 2,772,652 2,675,978 1,035,747 (note 7) (note 8) |
2022 2021 £ £ 227,166 219,487 39,111 27,212 1,947,203 1,843,568 2,213,480 2,090,267 - 251,460 1,229,174 1,434,743 3,442,654 3,776,470 2022 2021 £ £ 2,869,352 2,509,946 55,770 144,369 2,925,122 2,654,315 2022 2021 £ £ 79,432 40,648 16,452 5,590 95,884 46,238 2022 2021 £ £ 764,095 716,935 764,095 716,935 Total Total 2022 2021 £ £ 1,905,600 1,661,931 759,951 447,088 533,160 529,951 383,667 233,788 242,691 - 238,943 - 503,336 282,206 720,316 402,942 427,217 511,742 94,742 82,674 674,754 616,090 6,484,377 4,768,412 |
|---|---|
30
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
| 6 Expenditure on charitable activities (continued) 2021 The comparative from last year is detailed below Cost of generating funds Charitable activities Grantmaking (note 11) Helplines Knowledge and Information Communications Health Services & Quality Improvements Campaigns Networks & Volunteering Membership costs 7 Staff costs Wages and salaries Social security costs Pension costs The average number of staff and the allocation of their time was: Charitable activities Direct Support Cost of generating funds |
Direct staff costs £ |
Direct other costs £ |
Support Total costs 2021 £ £ 326,699 1,661,931 27,269 447,088 91,180 529,951 32,913 233,788 54,408 282,206 56,783 402,942 79,772 511,742 17,670 82,674 131,677 616,090 818,371 4,768,412 2022 2021 £ £ 2,379,377 2,057,879 254,036 207,504 139,239 127,057 2,772,652 2,392,440 2022 2021 No. No. 37 33 15 12 19 16 71 61 |
|---|---|---|---|
| 684,123 163,347 418,609 159,969 222,531 266,923 160,088 63,380 253,470 2,392,440 |
651,109 256,472 20,162 40,906 5,267 79,236 271,882 1,624 230,943 1,557,601 |
||
The charity has 934 volunteers across the UK who provide awareness, fundraising and information sharing. Volunteers also supported the charity on a variety of internal panels, as well as in the media and as Trustees.
Key management compensation
Operational management of the charity is overseen by the Chief Executive, supported by a Senior Leadership Team of four (2021:five for part of the year reducing to four). Total remuneration, including pension costs in 2022 was £315,463 (2021: £400,355).
One member of staff was paid more than £80,000 and less than £90,000 in the year (2021: two). Two members of staff were paid more than £70,000 and less than £80,000 in the year (2021: one).
One member of staff was paid more than £60,000 and less than £70,000 in the year (2021: two). Pension contributions in respect of these staff members totalled £21,413 (2021: £24,854).
| 8 Support Costs Other staff related costs Premises costs Office operating costs Governance costs Included in support costs are the following: Amortisation of intangible fixed assets Depreciation of tangible fixed assets Property rental and service charges |
2022 2021 £ £ 107,147 80,543 539,302 376,767 361,464 340,200 27,834 20,861 1,035,747 818,371 144,642 144,642 64,895 90,658 324,471 326,297 |
|---|---|
Support costs are allocated across the activity areas of the charity on the basis of direct staff time related to the activity.
31
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
- 8a Net incoming/(outgoing) resources for the year - Group
| This is stated after charging:- Depreciation and amortisation Operating Leases Auditors' remuneration - Crohn's & Colitis UK Auditors' remuneration - NACC Merchandise Ltd 9 Direct cost of generating funds External costs of trading subsidiary National fundraising direct costs |
2022 2021 £ £ 209,537 235,300 324,470 331,238 13,920 12,876 2,850 2,650 2022 2021 £ £ 44,423 133,376 1,861,177 1,528,555 1,905,600 1,661,931 |
|---|---|
10 Trading Subsidiary
The charity has a wholly owned trading subsidiary NACC Merchandise Limited, a company incorporated in England & Wales Reg. no. 03297441. The company sells Christmas cards and other products. The company transfers its taxable profits to the charity. A summary of the trading results of the company is shown below. Audited accounts have been filed with the Registrar of Companies.
| Profit and loss account Turnover Cost of sales Gross profit Administrative expenses Interest receivable Net Profit/(loss) on ordinary activities Amount gift aided to Crohn's & Colitis UK Net Profit for the year Retained profit brought forward Retained profit carried forward 11 Grant making expenditure Medical research Living with IBD research Economic Cost of IBD Other - Local Grants made by Networks Grants written back in year Direct costs of grant making process |
2022 2021 £ £ 55,770 144,369 (41,352) (136,157) 14,418 8,212 (8,071) (5,822) - - 6,347 2,390 (6,347) (2,390) - - - - - - 2022 2021 £ £ 469,446 220,170 76,397 98,571 139,273 - 5,175 - (5,528) (47,487) 684,763 271,254 75,188 175,834 759,951 447,088 |
|---|---|
Research grants
Grants are awarded by Crohn's & Colitis UK Research Committees to fund research projects that have been approved by peer review. All grants are made to institutions and not individuals. Grants may be for equipment, consumables or salaries. Crohn's & Colitis UK does not contribute to the overhead costs of such institutions. During 2022 there were a number of grants that were underutilised amounting to a writeback of £5,528 (2021 £47,487).
32
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
11 Grant making expenditure (continued)
| Medical research Royal Devon & Exeter NHS Foundation University of Oxford Kings College London Nottingham Univ Hospital NHS Trust Sheffield Teaching Hospital NHS Foundation University of Edinburgh Newcastle University Kings College London University of Oxford Other grants Local Networks raised funds for local projects to which grants totalling £5,175 (2020 £0) were made. Social & Psychological Research Kings College London University of Gloucester Economic cost of IBD Kohlrabi Hex 12 Governance direct costs Auditors' remuneration - current year Legal and professional expenses Meetings and trustee expenses Other governance costs |
2022 2021 £ £ - 43,428 - 76,988 - 99,754 44,261 - 69,629 - 92,409 - 69,777 - 98,288 - 95,082 - 469,446 220,170 2022 2021 £ £ - 98,571 76,397 - 76,397 98,571 47,970 - 91,303 - 139,273 - 2022 2021 £ £ 13,286 12,876 687 2,585 11,073 4,566 2,788 834 27,834 20,861 |
|---|---|
13 Transactions with Trustees
No Trustee received any remuneration for their services as a Trustee.
A total of £2,252 (2021 - £0) was reimbursed to or paid on behalf of 10 (2021: 0) Trustees in respect of travelling expenses and other costs incurred in carrying out their responsibilities as Trustees.
14 Operating Leases
At 31 December 2022 the group had commitments under non-cancellable leases as follows:-
| Amounts payable within 1 year Amounts payable between 2 and 5 years |
Equipment Land and Equipment Land and Buildings Buildings 2022 2022 2021 2021 £ £ £ £ 5,023 27,550 5,929 335,191 7,561 - 3,693 27,933 12,584 27,550 9,623 363,124 |
|---|---|
Total operating lease expenditure recognised in the SOFA amounted to £324,470 (2021: £330,622).
33
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
15 Transfers
Transfers are made for a variety of reasons, between types of funds and between National and Local Networks, the note below illustrates these:
| National Transfers between national funds:- Tangible fixed assets movement in net book value (1) Intangible fixed assets movement in net book value (2) Network funds movement for the year (3) Transfers between national funds and restricted Total funds 2021 transfers between national funds Notes |
Unrestricted Designated Restricted Funds Funds Funds Total £ £ £ £ - - - - (19,814) 19,814 - - 144,642 (144,642) - - (30,833) 30,833 - - 3,864 - (3,864) - 97,859 (93,995) (3,864) - (note 22) (note 22) (note 23) 235,512 (235,512) - - |
|---|---|
-
The net movement of tangible fixed asset additions and disposals during the year.
-
The net movement of intangible fixed asset additions and disposals during the year.
-
The net movement for networks 2022 activity.
-
The net movement of restricted funds
16 Intangible fixed assets
All assets held for use by the Charity and Group
| Cost Brought forward 1 January 2022 Additions in year Disposals Carried forward at 31 December 2022 Amortisation Brought forward 1 January 2022 Charge for the year Disposals Carried forward at 31 December 2022 Net book value At 31st December 2022 At 31st December 2021 |
Software development Total £ £ 723,209 723,209 - - - - 723,209 723,209 409,962 409,962 144,642 144,642 - - 554,604 554,604 168,605 168,605 313,247 313,247 |
|---|---|
At 31 December 2022 there were no capital commitments (2021 : £0)
34
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
16 Tangible fixed assets (continued)
All assets held for use by the Charity and Group
| All assets held for use by the Charity and Group | |||||
|---|---|---|---|---|---|
| Leasehold | Fixtures | Computer | |||
| Improvements | and Fittings | Equipment | Total | ||
| Cost | £ | £ | £ | £ | |
| Brought forward 1 January 2022 | 461,291 | 90,217 | 147,219 | 698,727 | |
| Additions | - | 10,146 | 74,562 | 84,708 | |
| Disposals | - | - | - | - | |
| Carried forward at 31 December 2022 | 461,291 | 100,363 | 221,781 | 783,435 | |
| Depreciation | |||||
| Brought forward 1 January 2022 | 172,257 | 85,252 | 146,295 | 403,804 | |
| Charge for the year | 48,142 | 5,357 | 11,396 | 64,895 | |
| Disposals | - | - | - | - | |
| Carried forward at 31 December 2022 | 220,399 | 90,609 | 157,691 | 468,699 | |
| Net book value | |||||
| At 31st December 2022 | 240,892 | 9,754 | 64,090 | 314,736 | |
| At 31st December 2021 | 289,034 | 4,965 | 924 | 294,923 | |
| At 31 December 2022 there were no capital commitments (2021 : £0) | |||||
| 17 | Investments | Group | Charity | ||
| 2022 | 2021 | 2022 | 2021 | ||
| £ | £ | £ | £ | ||
| Market value of investments at 1 January 2022 | 2,255,723 | 1,092,384 | 2,255,723 | 1,092,384 | |
| Acquisitions at cost | 500,000 | 1,000,000 | 500,000 | 1,000,000 | |
| Unrealised gains/(losses) on investments | (312,141) | 163,339 | (312,141) | 163,339 | |
| Market value of investments at 31 December 2021 | 2,443,582 | 2,255,723 | 2,443,582 | 2,255,723 |
During 2022 the charity invested a further £0.5m with fund managers in the same ethical investments fund. The Charitable company's balance sheet also includes a £1 investment in NACC Merchandise Ltd (see note 10).
| 18 Debtors All amounts fall due within one year Balance with trading subsidiary Prepayments Tax recoverable Other debtors Accrued income |
Group Charity 2022 2021 2022 2021 £ £ £ £ - - 18,740 - 340,672 361,109 337,471 321,560 39,110 18,465 39,110 18,465 239,599 366,255 239,599 405,804 2,134,885 1,316,221 2,134,885 1,316,221 2,754,266 2,062,050 2,769,806 2,062,050 |
|---|---|
35
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
| 19 Analysis of cash at bank and in hand Current accounts and cash balances Interest-bearing account balances Local Networks 20 Creditors: amounts falling due within one year Unpaid balances of research grants Trade creditors Balance with trading subsidiary Social security and other taxes Accruals and deferred income Deferred income reconciliation Balance brought forward Amount recognised in the year Amount deferred in the year Balance carried forward Creditors: amounts falling due after one year Unpaid balances of research funds 21 Provisions for liabilities Dilapidations provision |
2022 2021 £ £ 486,338 200,228 1,910,453 1,809,670 213,971 232,873 2,610,762 2,242,771 2022 2021 £ £ 1,255,556 896,164 361,129 320,449 - - 72,641 54,741 301,324 164,449 1,990,650 1,435,803 - 129,747 - (129,747) 9,154 - 9,154 - 2022 2021 £ £ 459,542 439,277 2022 2021 £ £ 108,000 - Group Group Group Group |
2022 2021 £ £ 414,254 186,993 1,910,453 1,809,670 213,971 232,873 2,538,678 2,229,536 2022 2021 £ £ 1,255,556 896,164 304,586 267,666 - 39,549 72,641 54,741 301,324 164,449 1,934,107 1,422,569 - 129,747 - (129,747) 9,154 - 9,154 - 2022 2021 £ £ 459,542 439,277 2022 2021 £ £ 108,000 - Charity Charity Charity Charity |
|---|---|---|
This relates to dilapidations on the office lease agreement.
36
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
22 Unrestricted funds
| Designated funds: Tangible fixed assets (a) Intangible fixed assets (b) Networks retained funds (c) Designated total Other unrestricted funds General Reserve Fund held Nationally Non charitable trading funds Total |
2022 Brought forward £ 294,923 313,247 202,717 810,887 3,461,054 - 3,461,054 4,271,941 |
Income £ - - - - 5,476,808 55,770 5,532,578 5,532,578 |
Expenditure £ - - - - 4,822,721 55,770 4,878,491 4,878,491 |
2022 Carried Transfers forward £ £ 19,814 314,737 (144,642) 168,605 30,833 233,550 (93,995) 716,892 97,859 4,213,000 - - 97,859 4,213,000 3,864 4,929,892 |
|---|---|---|---|---|
-
(a) A fund is maintained that represents the net book value of tangible fixed assets in so far as these funds are not available for immediate use.
-
(b) A fund is maintained that represents the net book value of intangible fixed assets in so far as these funds are not available for immediate use.
-
(c) The Trustees have agreed that accumulated surpluses from the Networks should be designated for future use by Networks. Networks are required to utilise these funds within three years in which they are reported.
| Unrestricted funds Designated funds Tangible fixed assets (a) Intangible fixed assets (b) Networks retained funds (c) Designated total Other unrestricted funds General Reserve Fund held Nationally Non charitable trading funds Total |
2021 Brought forward £ 385,581 457,889 202,929 1,046,399 1,290,085 - 1,290,085 2,336,484 |
Income £ - - - - 5,590,113 144,369 5,734,482 5,734,482 |
Expenditure £ - - - - 3,654,656 144,369 3,799,025 3,799,025 |
2021 Carried Transfers forward £ £ (90,658) 294,923 (144,642) 313,247 (212) 202,717 (235,512) 810,887 235,512 3,461,054 - - 235,512 3,461,054 - 4,271,941 |
|---|---|---|---|---|
37
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
| 23 Restricted funds 1 Ambassador video 2 Community Health Care Professional awareness project 3 Early Diagnosis 4 Ethnicity, Diversity and Inclusion research bid 5 Economic Cost of IBD 6 Gut Reaction 7 Facebook live 8 Health Foundation 9 Helplines (consolidated) 10 IBD Boost 11 IBD Nurses (consolidated) 12 In Their Shoes 13 Knowledge & Evidence support Helmsley 14 Margaret Ann Halls Legacy Fund 15 Medicine Decision Aid tool 16 Not Every Disability is Visible 17 Patient Information (consolidated) 18 Precision Medicine 19 Research (consolidated) 20 Research - Medical Research Council 21 Sprint Campaign 22 Supported Self Management in IBD 23 Wales Project 24 Website Development work 25 Funds under £5k Total restricted funds |
2022 2022 Brought Carried forward Income Expenditure Transfers forward £ £ £ £ £ - 12,000 12,000 - - 1,399 - - - 1,399 - 60,000 - - 60,000 - 55,000 55,000 - - - 50,000 139,276 - (89,276) - 34,796 34,797 1 - 13,280 - 8,480 - 4,800 125,544 140,000 145,861 - 119,683 2,100 268,672 198,995 - 71,777 6,397 - 6,398 1 - 8,348 40,268 44,386 - 4,230 24,864 - - 1,449 26,313 20,404 116,624 85,152 - 51,876 248,135 - 171,996 - 76,139 - 11,500 11,500 - - 10,703 - 1 (5,314) 5,388 69,315 115,133 174,798 - 9,650 2,000 7,000 9,000 - - 484,724 476,104 513,140 - 447,688 - 206,422 206,422 - - - 20,000 20,000 - - 4,479 29,782 20,826 - 13,435 - 10,000 9,999 (1) - - 50,000 50,000 - - - 765 - - 765 |
|---|---|
| 1,021,692 1,704,066 1,918,027 (3,864) 803,867 |
1 Ambassador video - Filming two videos with two of our Ambassadors talk about their diagnosis journey
2 Community HCP awareness project - deliver an education and awareness campaign for Community Health Care Professionals
3 Early Diagnosis - to address issues around public awareness of symptoms, the varying degree of awareness of IBD symptoms amongst GP's and availability of diagnostic tests
4 EDI research bid - understanding how ethnicity affects participation in research by people with Crohn's and Colitis
5 Economic Cost of IBD - The economic impact of diagnostic delay in IBD on the patients and NHS. With this particular fund the claim for the income has not yet been completed (and therefore not received) so there is a short term timing difference with the income anticipated in early 2023)
6 Gut Reaction - the Health Data Research UK Digital Innovation Hub for IBD combining data to support IBD research
7 Facebook live - holding live sessions to give advice and insight, and to empower those affected to control their daily lives
8 Health Foundation - lead the "Aware-IBD" project, working with people with IBD to design improvements to their care
9 Helplines - funds received to support the running and staffing of the Charity's helplines
10 IBD Boost - provide support for research to optimise management of symptoms via a digital self-management platform
11 IBD Nurses - funding to support the achievement of the IBD Standard regarding provision and access to IBD Nurses
12 In Their Shoes - to help everyone understand what sufferers of the disease experience
-
13 Knowledge & Evidence support Helmsley - to provide operating support for Crohn's & Colitis UK to continue to develop core operations of their programs for people with Crohn's and Colitis - the funding of two Knowledge and Evidence staff
-
14 Margaret Ann Halls Legacy Fund - combining support for the charity Helplines programme and funding for IBD nurses
-
15 Medicine Decision Aid tool - To develop a new user friendly digital decision tool providing a reliable and trusted source of medication information to the IBD Community
-
16 Not Every Disability is Visible - promoting accessible toilet signage to help raise awareness
-
17 Patient Information - supporting the re-printing and distribution of patient literature provided to hospitals
-
18 Precision Medicine - research study devising strategies to help patients identify benefits from certain drugs
-
19 Research - Research grants awarded - consolidated
38
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK Notes to the Accounts
For the year ended 31 December 2022
-
23 Restricted funds (continued)
-
20 Research - Medical Research Council support to fund early career researchers undertaking medical research
-
21 Sprint Campaign - raise awareness and understanding of IBD to support and empower a wider recognition of symptoms
-
22 Supported Self Management in IBD - programme for delivery of education and support to patients working with hospital IBD services in Scotland
-
23 Wales Project - compilation of a Welsh blueprint document, bringing all the findings of IBD Wales to date together which will give everyone in Wales , living with IBD , a much improved quality of life
-
24 Website Development work - Development of the new Crohns & Colitis UK website hub
-
25 Funds under £5k - grouping of small restricted funds.
| National Chatbot Communications and Digital Community HCP awareness project Gut Reaction Facebook live Health Foundation Helplines IBD Boost IBD Nurses In Their Shoes Knowledge & Evidence support Helmsley Margaret Ann Halls Legacy Fund Not Every Disability is Visible Patient & Public Involvement Patient Information Precision Medicine Research Research - Medical Research Council Sprint Campaign Supported Self Management in IBD Total restricted funds |
2021 2021 Brought Carried forward Income Expenditure Transfers forward £ £ £ £ £ - 9,643 9,643 - - - 18,000 18,000 - - - 9,000 7,601 - 1,399 - 62,655 62,655 - - - 13,280 - - 13,280 - 167,585 42,041 - 125,544 10,501 94,936 103,337 - 2,100 14,074 - 7,677 - 6,397 57,065 43,199 91,916 - 8,348 24,864 3,603 3,603 - 24,864 - 53,466 33,062 - 20,404 - 248,135 - - 248,135 53,246 - 42,543 - 10,703 3,500 - 3,500 - - - 112,549 43,234 - 69,315 - 64,500 62,500 - 2,000 188,844 220,462 75,418 - - 484,724 - 324,742 324,742 - - - 15,000 15,000 - - - 14,891 10,412 - 4,479 |
|---|---|
| 352,094 1,475,646 806,048 - 1,021,692 |
39
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
24 Analysis of Charity net assets between funds
| Fund balances at 31 December 2022 are represented by: Fixed assets Investments Current assets Current liabilities Long term liabilities Provisions for liabilities Fund balances at 31 December 2021 are represented by: Fixed assets Investments Current assets Current liabilities Long term liabilities Provisions for liabilities |
Unrestricted £ 483,341 2,443,582 2,846,063 (735,094) - (108,000) 4,929,892 Unrestricted £ 608,170 2,255,722 1,947,688 (539,639) - - 4,271,941 |
Restricted Total £ £ - 483,341 - 2,443,582 2,518,965 5,365,028 (1,255,556) (1,990,650) (459,542) (459,542) - (108,000) 803,867 5,733,759 Restricted Total £ £ - 608,170 - 2,255,722 2,357,133 4,304,821 (896,164) (1,435,803) (439,277) (439,277) - - 1,021,692 5,293,633 |
|---|---|---|
25 Related Party
Apart from the Gift Aid transfer of profits from NACC Merchandise Ltd as detailed in Note 10, the recharged administration and merchandise (2021: £8,603) there are no other related party transactions in the year (2021 none).
At the year end the subsidiary owed the charity £18,740 (2021: the charity owed the subsidiary £39,549).
26 Gifts in kind
Crohn's & Colitis UK received gifts in kind during the year relating to the goods and services to. a value of £94,022 (2021 £160,272).
This related to Google grants (US$107,697 converted at $1.21/£1 @ 31.12.22) £89,022 and also HR work at a value of £5k (2021: £25k).
The organisation would not have undertaken this work if the services had not been gifted. Consequently, these amounts have not been included in the financial statements as their value is not considered to be material.
40
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Crohn’s & Colitis UK
Notes to the Accounts
For the year ended 31 December 2022
| 27 Consolidated Statement of Financial Activities for the year ended 31 December 2021 Income : Donations and legacies 2 Charitable activities 5 Other trading activities 3 Investments 4 Other Total income Expenditure : Raising funds 9 Charitable activities: Grant making 11 Helplines Knowledge and Information Communications Health Services & Quality Improvements Campaigns Networks & volunteering Membership Total expenditure 6 Net income before investment gains/(losses) Gains/(losses) on investments 17 Net income Transfers between funds 15 Net movement in funds Reconciliation of funds: Total funds brought forward Total funds carried forward |
Unrestricted Restricted Total funds funds funds 2021 2021 2021 £ £ £ 3,158,790 617,680 3,776,470 708,135 8,800 716,935 1,805,149 849,166 2,654,315 46,238 - 46,238 16,170 - 16,170 |
|---|---|
| 5,734,482 1,475,646 7,210,128 |
|
| 1,661,931 - 1,661,931 127,587 319,501 447,088 426,614 103,337 529,951 153,992 79,796 233,788 254,563 27,643 282,206 265,676 137,266 402,942 373,237 138,505 511,742 82,674 - 82,674 616,090 - 616,090 |
|
| 3,962,364 806,048 4,768,412 |
|
| 1,772,118 669,598 2,441,716 163,339 - 163,339 |
|
| 1,935,457 669,598 2,605,055 - - - |
|
| 1,935,457 669,598 2,605,055 2,336,484 352,094 2,688,578 |
|
| 4,271,941 1,021,692 5,293,633 |
41
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Administrative details
Board of Trustees, officers and senior leadership team
Vice Presidents Rod Mitchell Elaine Steven
Board of Trustees Sue Cherrie resigned as Director and Chair on 5 May 2022 Jackie Craissati appointed as Director on 4 May 2022 and Chair from 6 May
Tom Reddy (Vice Chair) Sarah Denselow (Hon Secretary) resigned on 5 May 2022 Graham Bell Manpreet Dhesi appointed on 1 October 2022 Joanne Fillingham resigned on 31 January 2023 Lindsay Keir Ashish Patel Ian Patrick appointed on 1 October 2022 Amanda Quincey Alice Rath resigned as Director on 4 May 2022 Justine Woolf
Co-opted Advisers Dr Barney Hawthorne – Chief Medical Adviser Isobel Mason - IBD Nursing Adviser
Senior Leadership Team Sarah Sleet, Chief Executive Andrew Adie, Director of Finance and Corporate Services Ruth Wakeman, Director of Services, Advocacy and Evidence Claire Walsh, Director of Income Generation and Marketing
Professional services
Auditors Price Bailey LLP 3 Floor 24 Old Bond Street Mayfair LONDON W1S 4AP
Solicitors Debenhams Ottaway Ivy House 107 St. Peter’s Street St. Albans Herts AL1 3EW
Bankers Principal bankers: Lloyds Bank plc 36 Chequer Street St. Albans Herts AL1 3YQ
42
Crohn’s & Colitis UK
Annual Report and Financial Statements 2022
Other bankers: CCLA Senator House 85 Queen Victoria Street LONDON EC4V 4ET Close Brothers Treasury 10 Crown Plaza London EC2A 4FT
Metro Bank One Southampton Row London, WC18 5HA
Santander Corporate & Commercial 2 Triton Square, Regent's Place, London, NW1 3AN
For more information about who we are, what we do and how you can help, please get in touch.
Crohn’s & Colitis UK Helios Court 1 Bishops Square HATFIELD Herts AL10 9NE
www.crohnsandcolitis.org.uk
Follow us
Facebook: /crohnsandcolitisuk Twitter: @CrohnsColitisUK Instagram: @crohnsandcolitisuk YouTube: www.youtube.com/user/crohnsandcolitisuk LinkedIn: Crohns and Colitis UK
43